Acute Myeloid Leukemia Market Outlook:
Acute Myeloid Leukemia Market size was valued at USD 2.82 billion in 2025 and is expected to reach USD 7.65 billion by 2035, expanding at around 10.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of acute myeloid leukemia is assessed at USD 3.09 billion.
The number of acute myeloid leukemia patients is rising owing to aging population across the globe. Like many other malignancies, acute myeloid leukemia (AML) is a hematological neoplasm that typically affects the elderly, with a median age of presentation of 67 years. According to the World Health Organization (WHO), the number of individuals 60 years of age and over will double (to 2.1 billion) worldwide by 2050.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of acute myeloid leukemia is assessed at USD 3.09 billion.
The global acute myeloid leukemia market size was valued at over USD 2.82 billion in 2025 and is expected to expand at a CAGR of around 10.5%, surpassing USD 7.65 billion revenue by 2035.
North America acute myeloid leukemia market will hold around 40% share by 2035, driven by new therapies and rising leukemia incidence.
Key players in the market include Pfizer Inc., Novartis International AG, Celgene Corporation, Bristol-Myers Squibb Company, Amgen Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, Sanofi-Aventis (Genzyme Corporation), Sunesis Pharmaceutical Inc.
